The recent guidelines for pharmacotherapy of Parkinson’s Disease
By: Tomasz Karabin, Grazyna Biala and Marta Kruk-Slomka
References
- 1. Edinoff A, Sathivadivel N, McBride T, Parker A, Okeagu C, Kaye A, et al. Chronic pain treatment strategies in Parkinson’s disease. Neurol Int. 2020;12(3):61-76.
- 2. Radhakrishnan DM, Goyal V. Parkinson’s disease: A review. Neurol India. 2018;66(Suppl S1):26-35.
- 3. Pena-DIaz S, Ventura S. One ring is sufficient to inhibit α-synuclein aggregation. Neural Regen Res. 2022;17(3):508-11.
- 4. Chagraoui A, Boulain M, Juvin L, Anouar Y, Barrière G, Deurwaerdère PD. L-DOPA in Parkinson’s disease: Looking at the “False” neurotransmitters and their meaning. Int J Mol Sci. 2020;21(1):294.
- 5. Alborghetti M, Nicoletti F. Different generations of Type-B monoamine oxidase inhibitors in Parkinson’s disease: From bench to bedside. Curr Neuropharmacol. 2019;17(9):861-73.
- 6. Song Z, Zhang J, Xue T, Yang Y, Wu D, Chen Z, et al. Different catechol-O-methyl transferase inhibitors in Parkinson’s disease: A bayesian network meta-analysis. Front Neurol. 2021;12:707723.
- 7. Li BD, Bi ZY, Liu JF, Si WJ, Shi QQ, Xue LP, at al. Adverse effects produced by different drugs used in the treatment of Parkinson’s disease: A mixed treatment comparison. CNS Neurosci Ther. 2017;23(10):827-42.
- 8. Mao Q, Qin WZ, Zhang A, Ye N. Recent advances in dopaminergic strategies for the treatment of Parkinson’s disease. Acta Pharmacol Sin. 2020;41(4):471-82.
- 9. Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for Parkinson’s disease: Efficacy and safety of current and new formulations. CNS Drugs. 2019;33(9):905-18.
- 10. https://go.drugbank.com/ (access:11.05.2022)
- 11. Stoker TB, Barker RA. Recent developments in the treatment of Parkinson’s Disease. F1000research. 2020;9:F1000 Faculty Rev-862.
- 12. Ghossein N, Kang M, Lakhkar AD. Anticholinergic medications. In: StatPearls [Internet]. Treasure Island (FL); 2021.
- 13. Sharma VD, Lyons KE, Pahwa R. Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease. Ther Clin Risk Manag. 2018;14:665-73.
- 14. https://clinicaltrials.gov/ (access:11.05.2022)
- 15. Yang L, Wang H, Liu L, Xie A. The Role of Insulin/IGF-1/PI3K/Akt/GSK3β Signaling in Parkinson’s disease dementia. Front Neurosci. 2018;12:73.
Language: English
Page range: 80 - 85
Submitted on: Mar 5, 2022
Accepted on: Jun 10, 2022
Published online: Sep 2, 2022
Published in print: Aug 1, 2022
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2022 Tomasz Karabin, Grazyna Biala, Marta Kruk-Slomka, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.